# US 2010/0168767 A1 · Apparatus and methods for delivering hemostatic materials for blood vessel closure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168767 A1
- Document ID: US20100168767A1
- Status: Published application
- Kind: A1
- Application number: 12/492,779
- Filed: 2009-06-26
- Published: 2010-07-01
- Earliest claimed: 2008-06-30
- Assignees: Cardiva Medical, Inc.
- Inventors: Zia Yassinzadeh; Delfin Pelayo
- Web page: https://patentgrep.com/patent/US20100168767A1

## CPC

- A61B 17/0057: {Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect (sutures A61B17/04; closing rectum or urethra near body surface A61F2/0009)}
- A61B 2017/00004: {(bio)absorbable, (bio)resorbable or resorptive}
- A61B 2017/00623: {Introducing or retrieving devices therefor}
- A61B 2017/00654: {entirely comprised between the two sides of the opening}
- A61B 2017/00893: {pharmaceutically effective}
- A61B 2017/00898: {expandable upon contact with fluid}
- A61B 2017/22067: {Blocking; Occlusion (A61B2017/22054 takes precedence)}
- A61B 2090/3966: {Radiopaque markers visible in an X-ray image}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Apparatus for sealing a vascular wall penetration disposed at the end of the tissue tract comprises a shaft, an occlusion element, a hemostatic implant, and a protective sleeve. The apparatus is deployed through the tissue tract with the occlusion element temporarily occluding the vascular wall penetration and inhibiting backbleeding therethrough. The hemostatic implant, which will typically be a biodegradable polymer such as collagen carrying an anti-proliferative agent or coagulation promoter, will then be deployed from the sealing apparatus and left in place to enhance closure of the vascular wall penetration with minimum scarring. The implant may be radiopaque to allow observation before release.

## Claims

### Claim 1

Apparatus for sealing a blood vessel wall penetration disposed at an end of a tissue tract, said apparatus comprising:
a shaft having a proximal end and a distal end;
an occlusion element near the distal end of the shaft, said occlusion element being shiftable between a radially contracted configuration for passage through the tissue tract and a radially expanded configuration for deployment within the blood vessel to occlude the penetration;
a hemostatic implant disposed over or adjacent to an exterior surface of the shaft proximal to the occlusion element; and
a protective sleeve retractably disposed over the hemostatic implant.

### Claim 2 (depends on 1)

Apparatus as in claim 1, wherein the protective sleeve comprises an outer sleeve and a separately retractable inner release sheath.

### Claim 3 (depends on 2)

Apparatus as in claim 2, wherein the inner release sleeve is split to relieve constraint on the hemostatic implant after the outer sleeve is retracted over the inner release sleeve.

### Claim 4 (depends on 1)

Apparatus as in claim 1, further comprising a latch and a key element, wherein the latch is disposed on the shaft and engages the protective sleeve and wherein the key shifts the latch between a locking configuration which immobilizes the sleeve and an open configuration which allows the sleeve to be proximally retracted.

### Claim 5 (depends on 4)

Apparatus as in claim 4, wherein the latch is spring-loaded to deflect radially outwardly from the shaft to engage the sleeve and wherein the key element can radially depress the latch to release the sleeve.

### Claim 6 (depends on 5)

Apparatus as in claim 5, further comprising a back stop on the shaft, wherein the back stop engages the hemostatic implant to immobilize the implant while the sleeve is being proximally retracted, over the implant and the contracted occlusion element is being withdrawn past the implant.

### Claim 7 (depends on 6)

Apparatus as in claim 6, wherein the back stop comprises a tube disposed coaxially over the shaft and having a distal end which engages a proximal end of the hemostatic implant.

### Claim 8 (depends on 4)

Apparatus as in claim 4, wherein the key includes a coupling element which attaches to the protective sleeve as the latch is released, allowing the key to retract the protective sleeve.

### Claim 9 (depends on 1)

Apparatus as in claim 1, wherein the shaft comprises an outer tube and an inner rod and wherein the occlusion element has a distal end connected to a distal end of the rod and a proximal end connected to a distal end of the tube so that proximal retraction of the rod relative to the tube effects radial expansion of the occlusion element and distal advancement of the rod relative to the tube effects radial contraction of the occlusion element.

### Claim 10 (depends on 9)

Apparatus as in claim 9, wherein the occlusion element comprises a braided mesh covered by an elastic membrane.

### Claim 11 (depends on 1)

Apparatus as in claim 1, wherein the hemostatic implant comprises a body which circumscribes the shaft.

### Claim 12 (depends on 1)

Apparatus as in claim 1, wherein the hemostatic implant comprises a body which is configured to open laterally from the shaft.

### Claim 13 (depends on 1)

Apparatus as in claim 1, wherein the hemostatic implant comprises a swellable, biodegradable polymer, wherein the polymer is not fully hydrated when covered by the protective sleeve and hydrates when exposed by retracting the protective sleeve.

### Claim 14 (depends on 13)

Apparatus as in claim 13, wherein the biodegradable polymer comprises a material selected from the group consisting of polyethylene glycols, collagens, and gelatins.

### Claim 15 (depends on 1)

Apparatus as in claim 1, wherein the hemostatic implant comprises an active agent which comprises an anti-proliferative agent selected from the group consisting of sirolimus and paclitaxel, or an anticoagulant selected from the group consisting of thrombin and tissue factor.

### Claim 16 (depends on 15)

Apparatus as in claim 15, wherein the active agents are incorporated in a degradable carrier comprising a material selected from the group consisting of polylactic acid, and poly(lactic-co-glycolide).

### Claim 17 (depends on 16)

Apparatus as in claim 16, wherein the agents are incorporated in a nanoparticle.

### Claim 18 (depends on 17)

Apparatus as in claim 17, wherein the nanoparticles have an average size in the range from 10 nm to 100 □m.

### Claim 19 (depends on 1)

Apparatus as in claim 1, further comprising radiopaque marker(s) aligned within the hemostatic implant or the shaft.

### Claim 20 (depends on 19)

Apparatus as in claim 19, wherein the radiopaque markers are present on the hemostatic implant.

### Claim 21 (depends on 19)

Apparatus as in claim 19 wherein the radiopaque markers are present on the shaft.

### Claim 22

A method for sealing a blood vessel penetration disposed at the end of a tissue tract,
providing an apparatus including a shaft, an occlusion element, a hemostatic implant disposed on an exterior surface of the shaft;
introducing the shaft through the tissue tract to position the occlusion element in a lumen of the blood vessel and the hemostatic implant within the tissue tract, wherein the hemostatic implant is covered by a protective sleeve while the shaft is being introduced;
deploying the occlusion element to inhibit blood flow from the blood vessel into the tissue tract;
retracting the protective sleeve to expose the hemostatic implant;
collapsing the occlusion element; and
withdrawing the shaft and collapsed occlusion element past the hemostatic implant which remains in the tissue tract.

### Claim 23 (depends on 22)

A method as in claim 22, wherein the protective sleeve is latched to the shaft while the shaft is introduced, further comprising unlatching the sleeve before retracting the sleeve.

### Claim 24 (depends on 23)

A method as in claim 23, wherein unlatching comprises distally advancing a key over a latch on the shaft.

### Claim 25 (depends on 24)

A method as in claim 24, wherein the key and a proximal end of the sleeve lie proximally of the tissue tract when the occlusion element is deployed in the blood vessel lumen, wherein unlatching the latch and retracting the sleeve are performed by direct manipulation with a user's hands.

### Claim 26 (depends on 25)

A method as in claim 25, wherein the hemostatic implant is prevented from being displaced proximally by a back stop on the shaft while the sleeve is retracted and while the shaft is withdrawn.

### Claim 27 (depends on 25)

A method as in claim 25 wherein the key couples to the protective sleeve and the sleeve is retracted by retracting the key.

### Claim 28 (depends on 22)

A method as in claim 22, wherein the protective sleeve comprises an outer sleeve and an inner release sheath, wherein the outer sleeve is retracted first while the protective sheath inhibits sticking between the outer sleeve and the hemostatic implant.

### Claim 29 (depends on 28)

A method as in claim 28, wherein the inner release sheath is split so that it opens over the hemostatic implant before the sheath is retracted.

### Claim 30 (depends on 22)

A method as in claim 22, wherein the hemostatic implant comprises a cylindrical body which circumscribes the shaft.

### Claim 31 (depends on 22)

A method as in claim 22, wherein the hemostatic implant comprises a body which is configured to open laterally and release from the shaft after the protective sleeve is withdrawn.

### Claim 32 (depends on 22)

A method as in claim 22, wherein the hemostatic implant comprises a swellable, biodegradable polymer, wherein the polymer is not fully hydrated when covered by the protective sleeve and hydrates when exposed by retracting the protective sleeve.

### Claim 33 (depends on 32)

A method as in claim 32, wherein the biodegradable polymer comprises a material selected from the group consisting of polyethylene glycols, collagens, and gelatins.

### Claim 34 (depends on 22)

A method as in claim 22, wherein the hemostatic implant comprises an active agent comprising an anti-proliferative agent selected from the group consisting of sirolimus, paclitaxel, wherein the active agents are incorporated in a degradable carrier comprising a material selected from the group consisting of polylactic acid, and poly(lactide-co-glycolide).

### Claim 35 (depends on 34)

A method as in claim 34, wherein the hemostatic implant comprises an active agent which comprises an anti-proliferative agent selected from the group consisting of sirolimus and paclitaxel, or an anticoagulant selected from the group consisting of thrombin and tissue factor.

### Claim 36 (depends on 35)

A method as in claim 35, wherein the active agent is incorporated in a nanoparticle.

### Claim 37 (depends on 36)

A method as in claim 36, wherein the nanoparticles have an average size in the range from 10 nm to 100 m.

### Claim 38 (depends on 22)

A method as in claim 22, wherein at least a portion of the hemostatic implant or tube is radiopaque, wherein the method further comprises observing the hemostatic implant to determine that it has a correct orientation before the protective sleeve is retracted.
